Business Context and Reporting Period
Company: BIO-TECHNE Corp (Techne Corporation)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2001
Business Overview: A holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. The company operates in two main segments: Hematology Controls (clinical diagnostics) and Biotechnology Products (research reagents, cytokines, and assay kits). The company is the world's leading supplier of research and diagnostic cytokine products.
Key Financial Metrics
| Metric | Fiscal 2001 | Fiscal 2000 | Fiscal 1999 |
|---|---|---|---|
| Net Sales | $115,357,000 | $103,838,000 | $90,901,000 |
| Gross Margin | 75.4% | 74.2% | 69.9% |
| Net Earnings | $34,045,000 | $26,583,000 | $16,656,000 |
| Diluted EPS | $0.80 | $0.63 | $0.40 |
| Operating Cash Flow | $46,372,000 | $38,739,000 | $28,422,000 |
| Cash & Short-term Investments | $97,072,000 | $59,824,000 | $29,114,000 |
| Long-term Debt | $18,050,000 | $18,935,000 | $0 |
| Working Capital | $108,300,000 | $73,740,000 | $37,388,000 |
| R&D Expenses | $14,522,000 | $11,198,000 | $12,005,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% to $115.4 million, driven primarily by a 15% increase in Biotechnology Division sales ($73.7 million) and an 8% increase in Hematology Division sales ($14.7 million). R&D Europe sales grew 4% in USD terms (14% in GBP).
- Profitability: Net earnings rose 28% to $34.0 million. Gross margins improved to 75.4% from 74.2%, largely due to improved margins in the Biotechnology Division (78.6% vs 76.9%).
- Liquidity: Cash and short-term investments increased 62% to $97.1 million, reflecting strong operating cash flows of $46.4 million.
- Debt: The company carries a $20.4 million mortgage note (fixed at 7% for the first seven years) related to the 1999 purchase of its Minneapolis facilities. There were no borrowings on its $750,000 line of credit.
- Investments: The company increased its investment in ChemoCentryx, Inc. (CCX) and made a new $3 million equity investment in Discovery Genomics, Inc. (DGI) in August 2001.
Guidance, Outlook, and Risks
- Outlook: Management expects to meet future capital requirements through existing cash, operating cash flow, and investment maturities. Capital expenditures for fiscal 2002 are estimated at $8.8 million, including the completion of a parking ramp and facility expansions.
- Strategic Focus: Continued expansion of the Biotechnology product line (cytokines, antibodies, assay kits) and development of new hematology controls. The company plans to exercise an option to purchase adjacent real estate in fiscal 2002.
- Key Risks:
- Technological Obsolescence: Rapid changes in biotechnology and hematology instrumentation could render current products noncompetitive.
- Patent Litigation: The company has not conducted a patent infringement study for all products and faces potential infringement claims.
- Legal Contingency: Ongoing litigation with Amgen Inc. regarding invoices totaling $28 million. The company believes it owes no material amount, but an unfavorable outcome could materially affect net income.
- Regulatory: Delays in FDA approvals for clinical diagnostic kits could impact future revenue.
- Unusual Items: A one-time $1.2 million state income tax credit reduced the effective tax rate in fiscal 2001 to approximately 29%.
Investor Verification Checklist
- Amgen Litigation: Verify the status and potential financial impact of the $28 million dispute with Amgen Inc.
- ChemoCentryx Investment: Review the financial performance and valuation of the 26% equity stake in ChemoCentryx, Inc., which contributed operating losses.
- Discovery Genomics Deal: Assess the strategic value and financial terms of the August 2001 $3 million investment and license agreement with Discovery Genomics, Inc.
- Real Estate Options: Confirm the timeline and costs associated with the exercise of options to purchase adjacent properties in Minneapolis.
- Stock-Based Compensation: Note that the company follows APB Opinion No. 25; pro forma net earnings would be significantly lower ($16.6 million) if SFAS No. 123 fair value accounting were applied.